NO20026063L - Antistoffer mot human MCP-1 - Google Patents

Antistoffer mot human MCP-1

Info

Publication number: NO20026063L
Authority: NO; Norway
Prior art keywords: antibodies; human mcp; mcp; human
Prior art date: 2000-06-30

Application number

NO20026063A

Other languages

English (en)

Other versions

NO20026063D0 (no

Inventor

Peter Hiestand

Hans Hofstetter

Trevor Glyn Payne

Roman Urfer

Franco E Di Padova

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-30

Filing date

2002-12-17

Publication date

2003-02-27

2002-12-17 Application filed by Novartis Ag filed Critical Novartis Ag

2002-12-17 Publication of NO20026063D0 publication Critical patent/NO20026063D0/no

2003-02-27 Publication of NO20026063L publication Critical patent/NO20026063L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Obesity (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20026063A 2000-06-30 2002-12-17 Antistoffer mot human MCP-1 NO20026063L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0016138.0A GB0016138D0 (en)	2000-06-30	2000-06-30	Organic compounds
PCT/EP2001/007468 WO2002002640A2 (en)	2000-06-30	2001-06-29	Antibodies to human mcp-1

Publications (2)

Publication Number	Publication Date
NO20026063D0 NO20026063D0 (no)	2002-12-17
NO20026063L true NO20026063L (no)	2003-02-27

Family

ID=9894801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20026063A NO20026063L (no)	2000-06-30	2002-12-17	Antistoffer mot human MCP-1

Country Status (27)

Country	Link
US (1)	US20040047860A1 (no)
EP (1)	EP1299421B1 (no)
JP (2)	JP3920215B2 (no)
KR (1)	KR100603899B1 (no)
CN (1)	CN100486996C (no)
AR (1)	AR046379A1 (no)
AT (1)	ATE426616T1 (no)
AU (2)	AU8390301A (no)
BR (1)	BR0112086A (no)
CA (1)	CA2412775A1 (no)
CZ (1)	CZ20024256A3 (no)
DE (1)	DE60138102D1 (no)
EC (1)	ECSP024402A (no)
ES (1)	ES2322643T3 (no)
GB (1)	GB0016138D0 (no)
HU (1)	HUP0301477A3 (no)
IL (1)	IL153721A0 (no)
MX (1)	MXPA03000201A (no)
NO (1)	NO20026063L (no)
NZ (1)	NZ523195A (no)
PE (1)	PE20020125A1 (no)
PL (1)	PL207133B1 (no)
PT (1)	PT1299421E (no)
RU (1)	RU2314316C2 (no)
SK (1)	SK18122002A3 (no)
WO (1)	WO2002002640A2 (no)
ZA (1)	ZA200300199B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001066754A1 (en)	2000-03-03	2001-09-13	Cambridge Antibody Technology Limited	Human antibodies against eotaxin and their use
US6946546B2 (en)	2000-03-06	2005-09-20	Cambridge Antibody Technology Limited	Human antibodies against eotaxin
AU2002357770B2 (en)	2001-11-30	2008-07-31	Biogen Ma Inc.	Antibodies against monocyte chemotactic proteins
JP4468172B2 (ja) *	2002-08-19	2010-05-26	アブジェニックス・インコーポレーテッド	単球走化性タンパク質−１（ｍｃｐ−１）に対する抗体、およびその使用
CN1681926A (zh) *	2002-09-12	2005-10-12	财团法人化学及血清疗法研究所	人的抗人mcp－1抗体和该抗体的片段
WO2005044200A2 (en) *	2003-11-05	2005-05-19	Centocor, Inc.	Methods and compositions for treating mcp-1 related pathologies
WO2005108431A1 (en) *	2004-05-04	2005-11-17	University Of Kentucky Research Foundation	Methods and compositions for the treatment of ocular neovascularization
GB0412400D0 (en) *	2004-06-03	2004-07-07	Univ Newcastle	Treatment of inflammatory conditions
US8114964B2 (en) *	2005-05-19	2012-02-14	Centocor, Inc.	Anti-MCP-1 antibodies, compositions, methods and uses
TW200716174A (en) *	2005-05-19	2007-05-01	Centocor Inc	Anti-MCP-1 antibodies, compositions, methods and uses
EP2041568A4 (en) *	2006-06-15	2009-08-12		CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
ES2434039T3 (es) *	2006-07-24	2013-12-13	Yeda Research And Development Co. Ltd.	Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación
US20080076120A1 (en) *	2006-09-14	2008-03-27	Millennium Pharmaceuticals, Inc.	Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008060783A2 (en) *	2006-10-05	2008-05-22	Centocor Ortho Biotech Inc.	Ccr2 antagonists for treatment of fibrosis
AU2007337983A1 (en) *	2006-12-22	2008-07-03	Ablynx N.V.	Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
JP2011517548A (ja) *	2007-06-29	2011-06-16	セントコア・オーソ・バイオテツク・インコーポレーテツド	抗ｍｃｐ−１抗体、組成物、方法及び使用
WO2009061830A1 (en) *	2007-11-06	2009-05-14	Massachusetts Eye & Ear Infirmary	Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
JP5685535B2 (ja)	2008-08-18	2015-03-18	ファイザーインコーポレイティッド	Ｃｃｒ２に対する抗体
CA2734800C (en)	2008-08-20	2021-02-09	Probiodrug Ag	Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
RU2014144463A (ru) *	2009-06-25	2015-06-20	Фред Хатчинсон Кансэр Рисёч Сентер	Способ измерения адаптивного иммунитета
HK1208236A1 (en)	2012-06-22	2016-02-26	Sorrento Therapeutics, Inc.	Antigen binding proteins that bind ccr2
BR112017002980A2 (pt) *	2014-08-15	2017-12-12	Pixarbio Corp	composição para inibir a inflamação em um indivíduo com um dano na coluna vertebral, método para tratar inflamação em um indivíduo tendo um dano na coluna vertebral e kit para produzir a composição
CN104198727A (zh) *	2014-08-22	2014-12-10	广西南宁隆吉维特生物科技有限公司	人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
EP3050574B1 (en)	2015-01-28	2019-10-09	Universite De Bordeaux	Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
CN105695495B (zh) *	2015-12-07	2020-02-18	中国石油大学(华东)	一种高活性人趋化因子的制备方法及用途
US20180164221A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en)	2016-12-14	2018-06-21	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN108048408B (zh) *	2018-01-26	2020-02-07	扬州大学	牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
WO2020106754A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
US20220204608A1 (en)	2019-04-17	2022-06-30	Hiroshima University	Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
PE20221661A1 (es) *	2019-12-18	2022-10-26	Hoffmann La Roche	Anticuerpos anti-ccl2 biespecificos
CN112358547A (zh) *	2020-09-30	2021-02-12	浙江大学	抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN119684454B (zh) *	2024-12-25	2025-09-12	武汉爱博泰克生物科技有限公司	针对人mcp-1蛋白的抗体、抗体对和试剂盒及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9019552D0 (en) *	1990-09-07	1990-10-24	Unilever Plc	Specific binding agents
GB9115364D0 (en) *	1991-07-16	1991-08-28	Wellcome Found	Antibody
CA2572289A1 (en) *	2004-06-30	2006-08-17	Centocor, Inc.	Anti-mcp-1 antibodies, compositions, methods and uses

2000
- 2000-06-30 GB GBGB0016138.0A patent/GB0016138D0/en not_active Ceased
2001
- 2001-06-28 AR ARP010103086A patent/AR046379A1/es not_active Application Discontinuation
- 2001-06-28 PE PE2001000649A patent/PE20020125A1/es not_active Application Discontinuation
- 2001-06-29 CZ CZ20024256A patent/CZ20024256A3/cs unknown
- 2001-06-29 ES ES01962800T patent/ES2322643T3/es not_active Expired - Lifetime
- 2001-06-29 PL PL359854A patent/PL207133B1/pl not_active IP Right Cessation
- 2001-06-29 CN CNB018120652A patent/CN100486996C/zh not_active Expired - Fee Related
- 2001-06-29 RU RU2003100512/13A patent/RU2314316C2/ru not_active IP Right Cessation
- 2001-06-29 CA CA002412775A patent/CA2412775A1/en not_active Abandoned
- 2001-06-29 AU AU8390301A patent/AU8390301A/xx active Pending
- 2001-06-29 KR KR1020027017405A patent/KR100603899B1/ko not_active Expired - Fee Related
- 2001-06-29 SK SK1812-2002A patent/SK18122002A3/sk unknown
- 2001-06-29 EP EP01962800A patent/EP1299421B1/en not_active Expired - Lifetime
- 2001-06-29 BR BR0112086-7A patent/BR0112086A/pt not_active IP Right Cessation
- 2001-06-29 JP JP2002507891A patent/JP3920215B2/ja not_active Expired - Fee Related
- 2001-06-29 IL IL15372101A patent/IL153721A0/xx unknown
- 2001-06-29 MX MXPA03000201A patent/MXPA03000201A/es active IP Right Grant
- 2001-06-29 WO PCT/EP2001/007468 patent/WO2002002640A2/en not_active Ceased
- 2001-06-29 AU AU2001283903A patent/AU2001283903B2/en not_active Ceased
- 2001-06-29 DE DE60138102T patent/DE60138102D1/de not_active Expired - Lifetime
- 2001-06-29 PT PT01962800T patent/PT1299421E/pt unknown
- 2001-06-29 US US10/312,022 patent/US20040047860A1/en not_active Abandoned
- 2001-06-29 AT AT01962800T patent/ATE426616T1/de not_active IP Right Cessation
- 2001-06-29 HU HU0301477A patent/HUP0301477A3/hu unknown
- 2001-06-29 NZ NZ523195A patent/NZ523195A/en unknown
2002
- 2002-12-17 NO NO20026063A patent/NO20026063L/no not_active Application Discontinuation
- 2002-12-24 EC EC2002004402A patent/ECSP024402A/es unknown
2003
- 2003-01-08 ZA ZA200300199A patent/ZA200300199B/en unknown
2006
- 2006-11-21 JP JP2006314441A patent/JP2007054079A/ja active Pending

Also Published As

Publication number	Publication date
CN100486996C (zh)	2009-05-13
HUP0301477A3 (en)	2005-11-28
PT1299421E (pt)	2009-06-26
NO20026063D0 (no)	2002-12-17
NZ523195A (en)	2005-09-30
DE60138102D1 (de)	2009-05-07
AU8390301A (en)	2002-01-14
PL359854A1 (en)	2004-09-06
BR0112086A (pt)	2003-05-06
HUP0301477A2 (hu)	2003-08-28
EP1299421B1 (en)	2009-03-25
RU2314316C2 (ru)	2008-01-10
ES2322643T3 (es)	2009-06-24
PE20020125A1 (es)	2002-03-12
CN1443199A (zh)	2003-09-17
AU2001283903B2 (en)	2005-06-02
WO2002002640A2 (en)	2002-01-10
CA2412775A1 (en)	2002-01-10
JP3920215B2 (ja)	2007-05-30
SK18122002A3 (sk)	2003-06-03
US20040047860A1 (en)	2004-03-11
ECSP024402A (es)	2003-02-06
KR20030014272A (ko)	2003-02-15
JP2007054079A (ja)	2007-03-08
PL207133B1 (pl)	2010-11-30
GB0016138D0 (en)	2000-08-23
IL153721A0 (en)	2003-07-06
KR100603899B1 (ko)	2006-07-25
WO2002002640A3 (en)	2002-05-16
MXPA03000201A (es)	2003-05-27
CZ20024256A3 (cs)	2003-04-16
ATE426616T1 (de)	2009-04-15
ZA200300199B (en)	2003-11-13
AR046379A1 (es)	2005-12-07
JP2004502421A (ja)	2004-01-29
EP1299421A2 (en)	2003-04-09

Publication	Publication Date	Title
NO20026063L (no)	2003-02-27	Antistoffer mot human MCP-1
NO20023266D0 (no)	2002-07-05	Antistoffer mot humant IL-1
NO20030827D0 (no)	2003-02-21	Antistoffer mot human IL-1<beta>
NO20034554D0 (no)	2003-10-10	Antistoffer mot VLA-1
NO20041802L (no)	2004-04-30	Antistoffer mot human vevsfaktor
NO20042388L (no)	2004-08-09	Antistoff mot CD40
NO20004133D0 (no)	2000-08-18	Antistoffer mot human CD40
IS6779A (is)	2003-04-11	Mannlíkt mótefni gegn LT-beta-R
DE60142328D1 (de)	2010-07-22	Programmbereitstellungsvorrichtung
NO20041018L (no)	2004-03-10	Antistoffer mot OPGL
CY2012003I1 (el)	2016-12-14	Αντισωματα που συνδεονται ανοσοειδικως προς blys
AU4835001A (en)	2001-09-24	Antibodies to human cd154
DE60109358D1 (de)	2005-04-21	Lanzettenvorrichtung
NO20054170D0 (no)	2005-09-07	Antistoff mot human IL-21 reseptor og anvendelser derav
DE60124662D1 (de)	2007-01-04	Karosseriestruktur
DE60004082D1 (de)	2003-08-28	Einsatzbereite verbindungsvorrichtung
IS8266A (is)	2006-01-26	Breytt mennsk IGF-1R mótefni
EP1646401A4 (en)	2007-07-18	SPECIFIC HUMAN ANTIBODIES
DK200000305U3 (da)	2002-02-22	Ultralydapparat
FI20002373L (fi)	2002-04-28	Sydänrakenne
ATA7922000A (de)	2002-04-15	Elektromedizinisches gerät
FI20011171A0 (fi)	2001-06-04	Pilkki
SE0000819D0 (sv)	2000-03-10	Skin preparation
FI20002121L (fi)	2002-03-28	Liittorakenne
SK2720U (sk)	2000-12-11	Multifunkčné kreslo

Legal Events

Date	Code	Title	Description
2008-01-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application